- Editas Medicine press release ( NASDAQ: EDIT ): Q2 GAAP EPS of -$0.78 beats by $0.06 .
- Revenue of $6.36M (+1573.7% Y/Y) beats by $2.07M .
For further details see:
Editas Medicine GAAP EPS of -$0.78 beats by $0.06, revenue of $6.36M beats by $2.07MFor further details see:
Editas Medicine GAAP EPS of -$0.78 beats by $0.06, revenue of $6.36M beats by $2.07MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2...